| Assessment Status | Rapid Review Complete |
| HTA ID | 21046 |
| Drug | Ketoconazole |
| Brand | Ketoconazole HRA® |
| Indication | For the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years. |
| Assessment Process | |
| Rapid review commissioned | 26/10/2021 |
| Rapid review completed | 13/12/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that ketoconazole not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations, December 2022.
